In the November/December 2015 issue of PharmaVOICE, Rhett Johnson explains that to achieve better value, the health care industry must define what value looks like and measure how effectively it is being produced. To read the article, click here.
Assessment of the impact of earlier access to disease-modifying treatments with more convenient administration frequency in reducing the socioeconomic burden for multiple sclerosis patients in Europe
The socioeconomic impact of Multiple Sclerosis (MS) extends to various areas of a patient’s life including personal wellbeing and mental health, family life...